- Home
- LVLU vs SNY Comparison
LVLU vs SNY Comparison
Compare LVLU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- SNY
- Stock Information
- Founded
- LVLU 1996
- SNY 1994
- Country
- LVLU United States
- SNY France
- Employees
- LVLU N/A
- SNY N/A
- Industry
- LVLU Catalog/Specialty Distribution
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- SNY Health Care
- Exchange
- LVLU Nasdaq
- SNY Nasdaq
- Market Cap
- LVLU 11.3M
- SNY 113.4B
- IPO Year
- LVLU 2021
- SNY N/A
- Fundamental
- Price
- LVLU $4.45
- SNY $47.03
- Analyst Decision
- LVLU Hold
- SNY Buy
- Analyst Count
- LVLU 1
- SNY 4
- Target Price
- LVLU $15.00
- SNY $61.50
- AVG Volume (30 Days)
- LVLU 83.8K
- SNY 2.8M
- Earning Date
- LVLU 11-12-2025
- SNY 10-24-2025
- Dividend Yield
- LVLU N/A
- SNY 3.40%
- EPS Growth
- LVLU N/A
- SNY 118.56
- EPS
- LVLU N/A
- SNY 8.65
- Revenue
- LVLU $292,337,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- LVLU N/A
- SNY $2.01
- Revenue Next Year
- LVLU $2.53
- SNY $6.82
- P/E Ratio
- LVLU N/A
- SNY $10.74
- Revenue Growth
- LVLU N/A
- SNY 15.65
- 52 Week Low
- LVLU $2.98
- SNY $44.73
- 52 Week High
- LVLU $28.05
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- LVLU 55.20
- SNY 42.55
- Support Level
- LVLU $3.69
- SNY $46.79
- Resistance Level
- LVLU $4.79
- SNY $47.69
- Average True Range (ATR)
- LVLU 0.49
- SNY 0.71
- MACD
- LVLU 0.06
- SNY -0.27
- Stochastic Oscillator
- LVLU 46.43
- SNY 32.62
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.